

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* BOLGER JOHN C (Last) (First) (Middle) C/O FULGENT GENETICS, INC. 4978 SANTA ANITA AVENUE (Street) TEMPLE CITY CA 91780 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol Fulgent Genetics, Inc. [FLGT]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 09/30/2016	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Predecessor Unit Option (Right to Buy) ⁽¹⁾	\$0.05	04/13/2016		A		20,000		(2)	04/12/2026	Predecessor Class D Non-Voting Common Units ⁽¹⁾	20,000	\$0.00	20,000	D	
Predecessor Unit Option (Right to Buy) ⁽¹⁾	\$1.62	06/22/2016		A		20,000		(3)	06/21/2026	Predecessor Class D Non-Voting Common Units ⁽¹⁾	20,000	\$0.00	20,000	D	
Predecessor Unit Option (Right to Buy) ⁽¹⁾	\$0.05	09/30/2016		D			20,000	(4)	02/22/2026	Predecessor Class D Non-Voting Common Units ⁽¹⁾	20,000	(5)	0	D	
Predecessor Unit Option (Right to Buy) ⁽¹⁾	\$0.05	09/30/2016		D			20,000	(2)	04/12/2026	Predecessor Class D Non-Voting Common Units ⁽¹⁾	20,000	(5)	0	D	
Predecessor Unit Option (Right to Buy) ⁽¹⁾	\$1.62	09/30/2016		D			20,000	(3)	06/21/2026	Predecessor Class D Non-Voting Common Units ⁽¹⁾	20,000	(5)	0	D	
Issuer Stock Option (Right to Buy)	\$0.38	09/30/2016		A		2,631		(4)	02/22/2026	Issuer Common Stock	2,631	(6)	2,631	D	
Issuer Stock Option (Right to Buy)	\$0.38	09/30/2016		A		2,631		(2)	04/12/2026	Issuer Common Stock	2,631	(6)	2,631	D	
Issuer Stock Option (Right to Buy)	\$12.312	09/30/2016		A		2,631		(3)	06/21/2026	Issuer Common Stock	2,631	(6)	2,631	D	

Explanation of Responses:

1. Reflects securities of Fulgent Therapeutics LLC (the "Predecessor" or "Fulgent LLC"). Fulgent LLC is considered the predecessor of Fulgent Genetics, Inc. (the "Issuer") following completion of a reorganization transaction pursuant to which the Predecessor became a wholly owned subsidiary of the Issuer (the "Reorganization"), which was completed on September 30, 2016 in connection with the initial public offering of the Issuer and which is described in the Issuer's Registration Statement on Form S-1, as amended (File No. 333-213469). In the Reorganization, all options to purchase the Predecessor's Class D non-voting common units were cancelled in exchange for options to purchase shares of the Issuer's common stock at a ratio of 7.6-for-1.

2. The shares or units, as applicable, subject to the option vest over a period of four years, with 1/4th of such shares or units, as applicable, vesting 12 months after April 13, 2016, and 1/16th of the remaining shares or units, as applicable, vesting at the end of every three-month period over the remaining 36 months, subject to Mr. Bolger's continued service for the Predecessor or the Issuer on each vesting date.

3. The shares or units, as applicable, subject to the option vest over a period of four years, with 1/4th of such shares or units, as applicable, vesting 12 months after June 22, 2016, and 1/16th of the remaining shares or

units, as applicable, vesting at the end of every three-month period over the remaining 36 months, subject to Mr. Bolger's continued service for the Predecessor or the Issuer on each vesting date.

4. The shares or units, as applicable, subject to the option vest over a period of four years, with 1/4th of such shares or units, as applicable, vesting 12 months after February 23, 2016, and 1/16th of the remaining shares or units, as applicable, vesting at the end of every three-month period over the remaining 36 months, subject to Mr. Bolger's continued service for the Predecessor or the Issuer on each vesting date.

5. The securities were disposed of and cancelled in the Reorganization in exchange for options to purchase 2,631 shares of the Issuer's common stock.

6. The securities were received in the Reorganization in exchange for the cancellation of options to purchase 20,000 of the Predecessor's Class D non-voting common units.

Remarks:

/s/ Paul Kim as Attorney-in-Fact 10/04/2016

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.